viewCreso Pharma Ltd

Creso Pharma well-placed to benefit from Democratic majority in US Senate and potential cannabis reform

The US Democratic Party has secured the balance of power in US Senate which increases the likelihood of cannabis policy reform and the decriminalisation of cannabis in the country.

Creso Pharma Ltd - Creso Pharma confident of the impact of a Democratic majority in US Senate on cannabis reform
If legislation reform occurs, the company is confident in its ability to enter the US market swiftly

Creso Pharma Ltd (ASX:CPH) (OTCMKTS:COPHF) (FRA:1X8) has welcomed recent news of the US Democratic Party winning the balance of power in the US Senate – an outcome which increases the likelihood of the decriminalisation of cannabis and passing of the Marijuana Opportunity Reinvestment and Expungement (MORE) Act.

The MORE Act aims to remove cannabis from the US Controlled Substances Act and aims to erase certain federal convictions and essentially decriminalise cannabis for the first time on a national level.

This bill has already passed in the lower chamber (228 to 164) on Friday, December 4, 2020, and will now move to the Democratic-controlled senate.

The company is well-positioned to benefit from potential legislative change with existing operations in North America allowing easy access to world’s largest cannabis market.

“Historic moment for cannabis industry”

The MORE Act is expected to encourage investors and larger corporate entities that have previously been hesitant to become involved in the US cannabis industry due to federal prohibition, to drive the cannabis industry forward in the USA.

Creso Pharma non-executive chairman Adam Blumenthal said: “The recent election result is a historic moment for the cannabis industry in the USA and these developments leave Creso very well placed to capitalise, should cannabis ultimately be decriminalised in the US through the passing of the MORE Act.

“Importantly, the decision reflects the changing sentiment towards cannabis and its CBD derived products in the USA.”

Well-placed to meet demand

The US cannabis market is estimated to be worth US$130 billion by 2024 and Creso is exploring several near-term opportunities upon this US federal legislation occurring.

The company’s fully licensed 24,000 square foot cultivation growing facility, Mernova, is only 220 miles from the US border in an ideal location to be able to cater to the Canadian and US market.

Creso Pharma is confident that Mernova could scale up operations to meet potential demand from the US market.

Blumenthal said: “Creso has established distribution footprints in place, as well as an established product suite that it is able to quickly rolled out to satisfy large unmet demand from US customers.

“Our proximity to the US, through our wholly-owned subsidiary Mernova, provides a significant advantage for the company and we look forward to any potential legislative changes that will unlock the US market.”

Notably, as a listed vehicle with access to capital, Creso is also an attractive partner for merger and acquisition opportunities.

Quick facts: Creso Pharma Ltd

Price: 0.21 AUD

Market: ASX
Market Cap: $199.37 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Creso Pharma Ltd named herein, including the promotion by the Company of Creso Pharma Ltd in any Content on the Site, the Company receives from...


Creso Pharma subsidiary Mernova granted sales license from Health Canada

Creso Pharma (ASX:CPH) subsidiary Mernova managing director Jack Yu and vice president Isaac Allen joined Steve Darling from Proactive to discuss the granting of their sales license from Health Canada and what it allows them to do. Isaac Allen tells Proactive they are gearing up sales...

on 12/6/20

2 min read